Abbott Introduces NeuroSphere Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.

Abbott (NYSE: ABT) today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed. Approved by the U.S. Food and Drug Administration, the NeuroSphere Virtual Clinic has the potential to increase access to optimal treatment for patients suffering from chronic pain or movement disorders who don't live close to a care provider, have difficulty accessing care, or are unable to go to the doctor because of circumstances like COVID-19.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8828751-abbott-introduces-neurosphere-virtual-clinic/

Abbott's NeuroSphere Virtual Clinic gives patients the flexibility and comfort of receiving care anywhere* by connecting with their doctor via secure in-app video chat and an integrated remote programming feature, now available within the proprietary Abbott patient controller app. NeuroSphere Virtual Clinic enables clinicians to prescribe new treatment settings remotely to the patient's neurostimulation device using the clinician programmer app and a new, simple and secure remote care connection. This advancement gives patients confidence in their care and the convenience to manage their therapy in a way that fits their lifestyle.

"With NeuroSphere Virtual Clinic, physicians can communicate and digitally prescribe new stimulation settings remotely, allowing them to extend care beyond their clinic walls and optimize therapy management," said Timothy Deer , M.D., DABPM, president and chief executive officer of The Spine and Nerve Center of the Virginias in Charleston, W.Va. "This is a significant advancement for chronic pain patients."

"NeuroSphere Virtual Clinic solves considerable issues patients with movement disorders, such as Parkinson's disease or essential tremor, can have in obtaining the care they need," said Drew Falconer , M.D., neurologist and director, Inova Parkinson's and Movement Disorders Center in Fairfax, Va. "Often, patients must be off their medication overnight, so that their treatments can be adjusted properly, which can make it difficult for a patient to travel to their specialist. With NeuroSphere Virtual Clinic, patients can receive stimulation settings from their physicians in real time and remotely via cloud and Bluetooth-based technology, which is something we have never been able to do before. This opens up a world in which patients can receive the care they need anytime, anywhere."*

The NeuroSphere Virtual Clinic can also be helpful for people who live in areas — both rural and urban — with inadequate access to medical services. On average people living with movement disorders will travel over 150 miles to access specialists offering deep brain stimulation (DBS). 1 Without alternative solutions, such as digital and/or telehealth options, these patients are more likely to delay or forego much-needed care. 2 NeuroSphere Virtual Clinic brings the convenience and flexibility of telemedicine to neurostimulation therapy, further benefitting chronic pain and movement disorder patients with Abbott devices. Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.

"A decade ago, we started evaluating the hurdles that patients had to overcome to receive neuromodulation treatment, and we have been working ever since to find a better way to connect providers and patients – with the goal of empowering patients to decide how to access the care they need," said Keith Boettiger , vice president, Neuromodulation, Abbott. "We are continuing to make these kinds of investments and working with regulatory authorities to make these telehealth changes permanent, as we believe that patients should be able to receive the care they need, regardless of whether they can make it physically to the doctor's office."

The NeuroSphere Virtual Clinic is compatible with Abbott's suite of neuromodulation technologies, including Infinity™ DBS System for patients with Parkinson's disease and tremors of the upper extremities in adults with essential tremors; Proclaim™ XR SCS System for patients living with chronic pain of the trunk and/or limbs; and Proclaim™ DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia. This integration across all Abbott neuromodulation technologies highlights Abbott's relentless pursuit of patient-centered research and development methodologies that use neuroscience combined with cutting-edge technology to go beyond physical symptom relief to improve the lives of people with neurological disorders.

*Anywhere with a cellular or Wi-Fi connection and sufficiently charged patient controller.

For important safety information please visit the websites for Infinity DBS , Proclaim XR and Proclaim DRG devices.

About Neuromodulation
Neuromodulation is an essential treatment that works by delivering electrical treatment directly to a targeted area to alter nerve activity. Neuromodulation is often recommended for patients who suffer from chronic pain and certain movement disorders, such as Parkinson's disease and essential tremors. Currently, more than 50 million Americans suffer from chronic pain 3 , while almost one million people live with Parkinson's disease 4 and an estimated 7 million people live with an essential tremor 5 .

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at https://www.facebook.com/Abbott and on Twitter @AbbottNews .

1 Abbott Data on File.
2 Deloitte. Narrowing the rural-urban health divide. https://www2.deloitte.com/us/en/insights/industry/public-sector/virtual-health-telemedicine-rural-areas.html . Accessed Nov. 8, 2020 .
3 Centers for Disease Control and Prevention. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults – United States , 2016. https://www.cdc.gov/mmwr/volumes/67/wr/mm6736a2.htm . Accessed Oct. 7, 2020 .
4 Parkinson's Foundation. Statistics. https://www.parkinson.org/Understanding-Parkinsons/Statistics . Accessed Nov. 13, 2020 .
5 National Organization for Rare Diseases. Essential Tremor. https://rarediseases.org/rare-diseases/essential-tremor/ . Accessed Nov. 13, 2020 .

NeuroSphere™ Virtual Clinic Image 1

NeuroSphere™ Virtual Clinic Image 2

NeuroSphere™ Virtual Clinic Image 3

NeuroSphere™ Virtual Clinic Image 4

Chronic Pain Patient Journey

Abbott Logo

Cision View original content: https://www.prnewswire.com/news-releases/abbott-introduces-neurosphere-virtual-clinic-first-of-its-kind-remote-neuromodulation-patient-care-technology-in-the-us-301241981.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO

"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for third quarter of fiscal year 2025

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0 .70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025 to shareholders of record at the close of business on December 27, 2024 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic . Medtronic plc , headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiex Limited (ASX:CDX)

Cardiex Limited


Keep reading...Show less

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation Awareness Day

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC

"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected

FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilitation processes, and efficient hospital logistics, thus attracting more healthcare facilities to adopt robotic solutions. The market is characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for medical service robots. A report from Grand View Research said that the global medical service robots market size was estimated at USD 20.59 billion in 2024 and is projected to grow at a CAGR of 16.5% from 2025 to 2030. It said: "The growth can be attributed to the introduction of technologically advanced robotic equipment in the healthcare sector and the rise in per capita healthcare spending. Continuous advancements in technology, such as robotic catheter control systems (CCS), data recorders, data analytics, remote navigation, motion sensors, 3D-Imaging, and HD surgical microscopic cameras, are projected to drive industry growth. Furthermore, the introduction of swarm robotics is opening new opportunities for industry. It is a new approach to coordinating multi-robotic systems through swarm intelligence." Active Tech Companies in the markets today include Jeffs' Brands Ltd (NASDAQ: JFBR), Serve Robotics Inc. (NASDAQ: SERV), Symbotic Inc. (NASDAQ: SYM), Microbot Medical Inc. (NASDAQ: MBOT), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×